RECURRENT MEDULLOBLASTOMA
Clinical trials for RECURRENT MEDULLOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MEDULLOBLASTOMA trials appear
Sign up with your email to follow new studies for RECURRENT MEDULLOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a vaccine fight childhood brain cancer? new trial hopes so.
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a vaccine called PEP-CMV in 120 children and young adults with certain aggressive brain tumors (high-grade glioma, DIPG, or recurrent medulloblastoma). The vaccine targets a common virus (CMV) found in these tumors, aiming to train the immune system to attack the…
Matched conditions: RECURRENT MEDULLOBLASTOMA
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 02:00 UTC
-
RNA vaccine trial offers new hope for kids with recurrent brain cancer
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a personalized RNA vaccine for children and young adults (ages 3–39) whose medulloblastoma has returned after standard treatment. The vaccine is made from the patient's own tumor and aims to train the immune system to fight the cancer. The main goals are to see i…
Matched conditions: RECURRENT MEDULLOBLASTOMA
Phase: PHASE1 • Sponsor: University of Florida • Aim: ⭐️ VACCINE ⭐️
Last updated May 13, 2026 16:02 UTC
-
Promising targeted therapy for recurrent brain tumors in kids and young adults
Disease control Recruiting nowThis study is testing a drug called Lutathera in people aged 4 to 39 with certain aggressive brain tumors or meningiomas that have come back or are growing. The drug delivers radiation directly to tumor cells that show up on a special PET scan. The goal is to find the safest dose…
Matched conditions: RECURRENT MEDULLOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
Engineered immune cells target deadly childhood brain tumors in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment for children and young adults with medulloblastoma or similar brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack…
Matched conditions: RECURRENT MEDULLOBLASTOMA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 04, 2026 16:31 UTC